Hypercoagulability in Cushing's syndrome: From arterial to venous disease.
Cushing disease
Cushing syndrome
anticoagulation
cardiovascular disease
hypercoagulability
venous thromboembolism
Journal
Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
pubmed:
3
4
2021
medline:
21
9
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
Cushing's syndrome (CS) is associated with multisystemic complications; the hematological system is not spared. Alteration in hemostatic parameters and in vivo endothelial dysfunction lead to increased thrombotic events. Arterial and venous thrombotic events carry significant morbidity and mortality. Death from cardiovascular and pulmonary embolism account for more than 50% of mortality. Surgery is a critical period; close to 50% of events occur in the 1-2 months after intervention. The evaluation and risk stratification of patients with CS is key to prevent events, balancing the risk-benefit of anticoagulation in this population. This current review will focus on up-to-date data on epidemiology, pathophysiology and management of hypercoagulability in CS.
Identifiants
pubmed: 33795197
pii: S1521-690X(21)00013-0
doi: 10.1016/j.beem.2021.101496
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101496Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest There are no conflicts of interest to disclose.